
Evidence presented Sunday at the 76th Scientific Sessions of the American Diabetes Association comes as competition is heating up over a pair of therapies that combine insulin with a GLP-1 receptor agonist.
Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.

Evidence presented Sunday at the 76th Scientific Sessions of the American Diabetes Association comes as competition is heating up over a pair of therapies that combine insulin with a GLP-1 receptor agonist.

Intarcia Therapeutics anticipates filing for FDA approval at the end of the third quarter of 2016. At this year's ADA presentation, Julio Rosenstock, MD, said the insertion method for the novel therapy delivery device continues to improve.

In an ADA session called "Follow the Money," panelists led by Joslin Diabetes Center's Robert A. Gabbay, MD, PhD, FACP, discussed the diabetes cost burden, insulin costs, and payment models.

A poster at an ADA session on barriers and facilitators to novel care found that top concerns of patients with diabetes often have nothing to do with the disease. Other studies looked at which comorbidities contribute the most to readmissions or length of stay, and how an intervention that focused on transitions of care reduced A1C in patients with uncontrolled diabetes.

Robert M. Anderson, EdD, of the University of Michigan, has spent his career spreading a message that patients respond best when education programs address what they want, not what an expert thinks they need.

A commentary in the special issue of JAMA on obesity argues that the nation has reached a point where therapy can no longer undo the damage of poor diets and lack of exercise, and a reckoning of policy change is needed.

The appellate ruling flatly rejected the request to overturn regulators' approval of Horizon's tiered network. But this is not the end of litigation over the controversial plan.

Older patients and those with other complications are at greatest risk.

After reading two CDC accounts of this strange set of symptoms among gay men, Anthony S. Fauci, MD, recalls redirecting his research efforts to combat a disease that didn't even have a name.

The first study sheds light on the complex interaction between underlying metabolic risk and breast cancer.

Cardiovascular outcomes trials, new technologies, and the fight over what we eat will be featured at the upcoming 76th Scientific Sessions of the American Diabetes Association in New Orleans.

Donald B. Verrilli won key cases to keep intact the Affordable Care Act. With his winning argument in the 2015 case to extend marriage equality to all states, same-sex couples could no longer be denied the right to cover a spouse on an insurance policy or be named next-of-kin for medical decisions.

The 57-year-old music icon officially became the most high-profile victim of the nation's opioid epidemic.

The study highlights results from the population largely denied CGM coverage under Medicare.

The acquisition lets Myriad acquire the maker of EndoPredict, which just received reimbursement status from Aetna and meets ASCO guidelines for payment by Medicare contractors.

The proposal calls for 2-year and 10-year goals to gradually reduce Americans' salt intake. This strategy has been used in the past when it became clear that FDA would seek ways to limit sugar consumption.

Not everyone agrees that payers should risk losing these healthier consumers for the long haul.

Guidelines and an article in the issue take on the thorny question of how obese type 2 patients must be for surgery to be effective in improving glycemic control.

Part 1: See Part 2 in the September issue of Evidence-Based Diabetes Management.

Training seniors to manage their own diabetes takes many hands--most notably, those of the patients themselves. A look at how a diabetes management program serving a diverse population approaches this task.

The collaboration is the latest in a series of partnerships for diabetes care announced by the medical device maker.

Data sharing in precision medicine has not been without controversy. Some genetic testing companies say security on public databases is less than stellar, giving them a reason to decline sharing their information warehouses.

The practical document will be of greatest use to smaller hospitals still building antibiotic stewardship programs from scratch. CDC estimates that drug-resistant bacteria infect 2 million people a year and cause 23,000 deaths.

The largest group of endocrinologists first declared obesity a disease in 2012. Guidelines call for making relief of weight-related complications the first priority, not weight loss per se.

The smallest overall increase in the MMI in 15 years is masked by the fact that employees are bearing an increasingly large share of healthcare costs.

A recent study showed patients with type 2 diabetes did better if given the combination therapy at the outset than if given 1 of the components as monotherapy.

Finding diabetes and treating it early can prevent high healthcare costs in the long term, the authors day.

The updated label reflects research that shows how hard it is to consume key nutrients and maintain calorie limits in a diet overwhelmed by sugar. The label will be a legacy of First Lady Michelle Obama's focus on better nutrition to combat childhood obesity.

US and European professional societies coordinated their announcement to reduce confusion for physicians and payers.

The sequence of events that led to Thursday's complaint points to a coordinated effort to challenge Myriad Genetics' long-held position that it does not share information on public databases.